Our sincere thanks to Aarvik Employees, Board Members, Scientific Advisory Board members, Collaborators and Investors for their commitment and excellent work, guidance and support towards making another outstanding year in building Aarvik's Discovery Portfolio. We look forward to another exciting year. Happy Holidays and a Happy New Year. Image Courtesy: Allison Bruce
Aarvik Therapeutics Inc
Biotechnology Research
Hayward, California 925 followers
Engineering Precision Medicines
About us
Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.
- Website
-
http://www.aarviktx.com
External link for Aarvik Therapeutics Inc
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Hayward, California
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
31363 Medallion Dr
Hayward, California 94544, US
Employees at Aarvik Therapeutics Inc
Updates
-
We are super excited to announce that Aarvik Therapeutics Inc was recognized as a Global Elite Deep-Tech Startup, from a curated pool of 5000+ deep tech companies, by Evolv™ Silicon Valley, an initiative of CII (Confederation of Indian Industry). As a part of this initiative the Aarvik team was invited to present at the Evolv™ Next-Tech Conference (part of the B20 India Summit) held in New Delhi, India on August 24th. Thanks to Ram Reddy, Rajan Navani (Co-chairs of Evolv™ Next-Tech) and the CII team for creating this platform to showcase emerging, innovative startups that are at the fore front of solving unmet needs. Aarvik Therapeutics is a biotech company building novel therapeutics for oncology using its proprietary next generation MUTTA™ Antibody Drug Conjugate platform.
-
The Aarvik Therapeutics Inc team has put together an extensive review of the "Clinical Landscape of Antibody-Drug Conjugates (ADCs). This review has a focus on discontinued ADCs from the clinic, to learn lessons from them and to enable Next-Generation ADCs. Special thanks to Heather Maecker and Vidya Jonnalagadda for the countless hours spent in compiling this review article. Our sincere thanks to Hanson Wade Group for providing access to the Beacon Targeted Therapies Clinical Trials and Pipeline Database. We could not cite every possible reference in the ADC field because of reference limit in the review article. https://lnkd.in/ehyghuMc